Clinical experience with ¹⁸F-JK-PSMA-7 when using a digital PET/CT

Area of Science:

• Nuclear Medicine
• Radiopharmaceuticals
• Medical Imaging

Background:

• Digital PET/CT offers higher sensitivity than analog systems, necessitating protocol adjustments for dose and acquisition time.
• ¹⁸F-JK-PSMA-7 imaging performance on digital PET/CT requires evaluation, especially considering the potential impact of prior therapies on target expression.

Purpose of the Study:

• To assess the diagnostic performance of ¹⁸F-JK-PSMA-7 PET/CT on a digital system with an adapted protocol in prostate cancer (PCa) patients.
• To investigate the influence of previous hormonal or chemotherapeutic treatments on the detection of recurrent PCa using ¹⁸F-JK-PSMA-7 PET/CT.

Main Methods:

• A study involving 54 PCa patients with biochemical recurrence analyzed digital ¹⁸F-JK-PSMA-7 PET/CT performance.
• Protocols were adapted for digital systems, reducing administered dose by 20% and acquisition time by 50% compared to analog systems.
• The impact of prior treatments on recurrence detection was specifically evaluated.

Main Results:

• ¹⁸F-JK-PSMA-7-positive lesions were detected in 70.3% (38/54) of patients.
• No significant difference in detection rates was observed between patients who received hormonal/chemotherapy and those who did not.
• SUVmax values showed no significant differences between treatment groups in pelvic lymph nodes, metastatic sites, or the prostate region.

Conclusions:

• ¹⁸F-JK-PSMA-7 PET/CT on digital systems, with adapted dose and acquisition time, provides valuable diagnostic information for PCa patients experiencing biochemical recurrence.
• The imaging technique remains effective irrespective of prior hormonal or chemotherapeutic interventions.